ArticleEJNMMI research2020
Neuron-specific enolase has potential value as a biomarker for [
Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic impact of discordant lesions on [Frontiers in nuclear medicine · 2026Article
- A visualized machine learning model using noninvasive parameters to differentiate men with and without prostatic carcinoma before biopsy.Scientific reports · 2025Article
- Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases.International journal of molecular sciences · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.Scientific reports · 2024Article
- PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.European radiology · 2023Review
- Prostate Cancer Biochemical Recurrence Resulted Negative on [Tomography (Ann Arbor, Mich.) · 2022Article
- Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine.Endocrine connections · 2022Article
- The VISION Forward: Recognition and Implication of PSMA-/Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
- Value of Combined PET Imaging with [Cancers · 2021Article
- Biomarkers in Prostate-Specific Membrane Antigen Theranostics.Diagnostics (Basel, Switzerland) · 2021Review
- Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.Advances in urology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [
methodsRetrospective study of N = 66 advanced mCRPC patients with dual [
resultsIn total, 41/66 (62%) patients revealed at least one [
conclusionWe observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.